IRAS was discovered only recently 1 and is a highly unique protein with little structural similarity to known proteins listed in sequence databases. Nischarin was cloned as the mouse homologue of IRAS. 2 The amino-acid sequence of Nischarin is about 80% homologous with IRAS, with a main difference being that Nischarin lacks the N-terminal 244 amino acids of IRAS. 1, 2 Nischarin was reported 2 to interact with the cytoplasmic tail of the integrin a5subunit of the fibronectin receptor, and to inhibit cell migration and lamellipodia formation in transfected 3T3 cells. The human protein IRAS (hIRAS) was also found to interact with insulin receptor substrates (IRS) in HEK 293 cells and to enhance IRS4-dependent insulin activation of extracellularly regulated kinase, ERK1/2. 3 Herein, we report a new cellular role for IRAS, which is to allow PC12 cells to experience markedly less caspase-3 enzyme activity induced by apoptotic stimuli such as serum deprivation, thapsigargin, or staurosporine treatment. This decrease in apoptotic effector enzyme activity was accompanied by a decrease in the proportion of apoptotic cells presumably due to an increase in the delay to initiate apoptosis.
IRAS and Nischarin have been shown to exist in multiple tissues and cell lines. [1] [2] [3] [4] Rat IRAS is endogenously expressed in PC12 cells (Genbank EST 106159) as a 210 kDa immunoreactive protein (Figure 1a) , which is similar in size to the full-length form of Nischarin already detected in neuronal mouse cells. 2 Three clonal sublines (IE10, 6E7, and 7D5) were selected by transfecting hIRAS cDNA into PC12 cells, isolating single cells, and propagating under geneticin selection. In addition, two empty-vector clonal sublines (pcDNA3.1 and 7D5a) were isolated in parallel by the same procedure. Cytologically, the cell lines were indistinguishable under phase contrast microscopy. Transfection of hIRAS into PC12 cells led to the appearance of the 167 kDa human protein that was predominantly localized in the cytosol of cells (Figure 1a) . The exact relation between the 210 kDa rat IRAS (rIRAS) and the 167 kDa hIRAS protein is not fully known, since the rat homologue has only been partially sequenced (EST 106159). Based on rat and human tissue Northern blot analysis, 4 it has been suggested that alternative splicing may be responsible for two molecular weight forms of this protein. If we assume that the two proteins play the same role in PC12 cells, then hIRAS-expressing PC12 cells constitute a moderate overexpression model of IRAS.
IRAS and Nischarin exhibit 100% amino-acid homology over an amino-acid sequence domain identified to bind a5-integrin. 2 The integrins, particularly the fibronectin receptor, have been linked to cell survival pathways. Overexpression of the a5 subunit protects cell lines against apoptotic stimuli, in part by modulating the expression of the antiapoptotic protein Bcl2 by activating the PI3kinase/Akt pathway. 5, 6 In this context, we hypothesized that IRAS might also modulate the survival of cells. An increase in caspase-3 activity is an index of apoptosis. We therefore measured the activities of caspase-3-like proteases after serum deprivation and compared the hIRAS-expressing and -nonexpressing cell lines. No differences in caspase-3 basal activities could be observed between the five cell lines grown in 15% serumcontaining medium. However, by 3 h of serum starvation, caspase-3-like activities had increased dramatically in the control cells, attaining their plateau by 6 h (5.9-fold increase; Figure 1b ). By comparison, caspase-3 activities in hIRAStransfected cells (i.e., IE10 clone) were increased four-fold by 6 h of serum starvation, but remained statistically less than those of control cells (Figure 1b ) at least until 24 h in serumfree medium. As shown in Figure 1c , after 6 and 24 h of serum deprivation, higher levels of enzymatic activity were found in both control cell lines (pcDNA3.1 and 7D5a) compared to all hIRAS-expressing cell lines (IE10, 7D5 and 6E7 lines). Assay of Annexin V-FITC binding followed by flow cytometric measurements was next performed to evaluate quantitatively the apoptotic population in hIRAS-expressing and -nonexpressing cell lines. As shown in Figure 1d , about 60% of control cells (pcDNA3.1 and 7D5a clones) appeared apoptotic (Annexin V-FITC positive, lower right quadrant) after 48 h in serum-free medium. Under the same conditions, hIRASexpressing sublines (IE10, 7D5, and 6E7) showed a marked reduction in apoptotic populations (Figure 1d ). Thus, reduced caspase-3 activation in serum-deprived hIRAS-expressing cells seemed to correlate with a reduction in the apoptotic cell population. Next, cell growth rate and survival in serumcontaining medium or in serum-free medium, respectively, were assessed microscopically. In this set of experiments, the number of viable cells were recorded by counting trypan blue excluding cells with a hemocytometer after different periods of time. The growth curves indicated that hIRAS-expressing cells behave similarly as control cells in serum-containing medium (data not shown). However, serum deprivation resulted in the death of 45% control cells within 24 h versus that of 0% hIRAS-expressing IE10 cells (Figure 1e ). After 72 h serum deprivation, all the hIRAS-expressing clones (IE10, 7D5, and 6E7) showed a greater proportion of viable cells as assessed by trypan blue exclusion than control cell lines (pcDNA3.1 and 7D5a) (data not shown). Thus, another main difference between control cells and hIRAS-expressing cell lines is prolonged survival of the latter in serum-free conditions, which may be related to the decrease in caspase-3 activity and apoptotic cell population observed previously. When serum is readded after 24 h serum deprivation, we observed that hIRAS-expressing cell lines proved able to proliferate again in marked contrast with control cells that continued to die (56715% and 250767% of trypan blue excluding cells after 72 h in serum-containing medium for control and hIRAS-expressing cells, respectively; 100% refers to the viable cells recorded after 24 h serum deprivation in each cell line).
In an attempt to generalize that transfection of hIRAS delays PC12 cells apoptosis, treatments were next performed with two different cytotoxic agents, thapsigargin and staurosporine. Thapsigargin, a Ca 2 þ -ATPase inhibitor that increases intracellular calcium by inhibiting the uptake of calcium into the endoplasmic reticulum, is known to induce apoptosis in many cell types including PC12 cells. 7 Staurosporine, a protein kinase inhibitor, also induces apoptosis in PC12 cells. 8 Staurosporine treatment of PC12 cells induces a sustained elevation of intracellular calcium and accumulation of reactive oxygen species. 8 Both of these apoptotic stimuli are known to trigger caspase-3 activation. 7, 8 . Thapsigargin was applied to the cells in 5% serum-containing medium, and then caspase-3 activities were recorded. As shown in Figure 1f , thapsigargin (100 nM) enhanced caspase-3 activity in control cells (pcDNA3.1 clone). In contrast, no enhancement by thapsigargin of caspase-3 activity was observed in hIRAS-expressing cells (IE10 clone). Staurosporine (1 mM) was added to complete medium (containing 15% serum), thus excluding any impact of low serum concentration on caspase-3 activity. In this paradigm, the sublines stably expressing hIRAS (1E10 and 7D5) showed lower caspase-3 activation after 6 h treatment with 1 mM staurosporine compared to control cells (pcDNA3.1 and 7D5a clones) (Figure 1f ). Caspase-3 activity after 6 h was increased 3.6-and 8.8-fold in control sublines (pcDNA3.1 and 7D5a, respectively) versus 2.3-and 2.8-fold in hIRAS-expressing cells (IE10 and 7D5 clones respectively). We thus have confirmed the activation of this apoptosis effector enzyme by these two drugs, and in the process shown that hIRAS also inhibits the increase in caspase-3 activity in these conditions.
In summation, IRAS appears to impinge on a mechanism central to apoptosis induced by distinct stimuli and which lies upstream of the caspase-3 activation resulting at least in a delayed cell death. According to the results of Figure 1e , it seems that a continued proapoptotic stimulus (96 h serum deprivation, for example) eventually overrides the IRAS block of apoptosis. As readdition of serum at an earlier time point of apoptosis triggering (after 24 h serum deprivation) allowed the hIRAS-expressing cells to divide again, we speculate that hIRAS lowers the probability of initiation of the apoptotic program rather than prolonging each individual apoptotic event as described for caspase-3 inhibitors. 9 Thus, hIRAS blocks apoptosis before destruction of membranes and loss of phosphatidylserine asymmetry and seems to protect the cells from the loss of the proliferative potential. Intriguingly, it appears from the literature that expression of the a5 integrin subunit delays serum-deprivation-induced as well as staurosporine-induced apoptosis in a manner very similar to the one obtained by the transfection of hIRAS.
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The mechanism of action of IRAS remains unresolved at this time and is currently under investigation. Hypotheses have been tested according to the proteins that are known to interact with IRAS.
2,3 IRAS may be implicated either in the insulin or the integrin dependent survival pathway, both of which imply PI3-kinase activation. 11, 6 However, our assays to inhibit the protective effect of IRAS with LY294002 or wortmannin (two PI3-kinase inhibitors) were unsuccessful; although a little enhancement of caspase-3 activity in serumdeprived hIRAS-expressing clones was recorded, no significant increase in the proportion of apoptotic cells could be reached with these inhibitors (data not shown). Likewise, PD98059, an inhibitor of the ERK1/2 pathway, was unable to induce an increase in hIRAS-expressing apoptotic cells (data not shown).
Our study has thus identified a new cellular role for the recently cloned human protein IRAS. We demonstrated that hIRAS expression in PC12 cells results in protection against apoptosis over a 2-3-day period of time. Although the mechanism of action of IRAS is not resolved, it may represent a previously unknown class of protein modulating the fine regulation of cell death and growth.
